Greg C. Flynn, Ph.D.

Dr. Flynn has over 20 years of experience in development and characterization of biologics, recombinant proteins, monoclonal antibodies, biosimilars and ADCs.  That experience includes extensive development, qualification and validation of analytical methods and efforts to understand and control critical quality attributes for protein therapeutics. He has held key roles in the development and implementation of Quality by Design principles at Amgen.  Implementation of Quality by Design included contributing towards and reviewing many regulatory filings. He has more than 50 scientific publications, including dozens focusing on the safety and efficacy of product quality attributes on protein therapeutics. Previous experience includes scientific project team leadership, technology development leadership, process team leadership, and formulation development.

​

Prior to joining Pharmefex, Dr. Flynn worked at Amgen for 13 years in a number of capacities, most recently as Scientific Director of Attribute Sciences. Prior to joining Amgen, he was a Senior Scientist at Baxter, Inc. and was a faculty member of the Chemistry Department and member of the Institute of Molecular Biology at the University of Oregon. He holds a Ph.D. in Chemistry (Biochemistry) from the University of California, Santa Barbara and was a Postdoctoral Fellow at Princeton University.